PI3K mTOR Inhibitor Compound Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K and mTOR inhibitors lack selectivity, leading to adverse effects due to inhibition of other kinase targets, and there is a need for compounds with high selectivity and good pharmacokinetics for effective cancer treatment.
Innovation Solution
Development of a compound with a specific formula that selectively inhibits PI3K and/or mTOR kinases, characterized by various substituents and functional groups, which is used in a pharmaceutical composition for treating proliferative diseases, including cancer, with a method for administering a therapeutically effective amount to achieve targeted inhibition.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticancer drugs are used to treat tumors, then the treatment can be administered, but the drugs do not distinguish between tumor cells and normal cells, causing serious side effects
Solution Approach 1:
The patent segments the kinase family into specific subclasses (PI3K and mTOR) and designs inhibitors that target these specific segments while avoiding other kinase segments. The compound structure is specifically designed to fit the ATP-binding pocket of PI3K/mTOR kinases with high selectivity, thereby segmenting the broad kinase inhibition into targeted inhibition of specific cancer-relevant kinases.
2Adaptability or versatility
If PI3K and mTOR inhibitors are developed as medicament, then targeted inhibition of cancer cells can be achieved, but no inhibitor has reached the market due to lack of selectivity and good pharmacokinetics
Solution Approach 1:
The patent applies local quality by designing specific functional groups and substituent patterns at particular positions of the molecule (e.g., R1, R2, R3, R4 groups in the general formula) to enhance binding affinity and selectivity for PI3K/mTOR kinases. The local chemical environment is optimized to interact specifically with amino acid residues in the kinase binding pocket, achieving both targeted inhibition and improved pharmacokinetic properties.
Solution Approach 2:
The patent systematically varies chemical parameters such as substituent types, chain lengths, ring structures, and functional groups to optimize the balance between selectivity and pharmacokinetics. By changing molecular weight, lipophilicity, hydrogen bonding capacity, and other physicochemical parameters, the compound achieves improved oral bioavailability and reduced off-target effects while maintaining potent inhibition.
3Productivity
If kinase inhibitors are designed to inhibit PI3K and mTOR, then cancer cell proliferation can be inhibited, but the high homology of kinases causes the compound to inhibit other kinase targets, showing harmful adverse effects or toxicity
Solution Approach 1:
The patent introduces asymmetry in the molecular structure to achieve selectivity. The compound features asymmetric substitution patterns and chiral centers that create a specific three-dimensional configuration optimized for binding to PI3K/mTOR kinases. This asymmetric design prevents the compound from fitting into the slightly different binding pockets of other kinase families, thereby reducing off-target inhibition and associated toxicity.
Data Source
AI summary
The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt, a stereoisomer or a solvate thereof, wherein R1, R2, R3, R4, X, Y, A and B are as defined in the specification. The present invention further relates to a method for preparing these compounds, a pharmaceutical composition containing these compounds, and a use of these compounds in manufacture of a medicament for treating and/or preventing proliferative diseases.